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Articles
High-dose rifampicin, moxiﬂ oxacin, and SQ109 for treating 
tuberculosis: a multi-arm, multi-stage randomised 
controlled trial
Martin J Boeree*, Norbert Heinrich*, Rob Aarnoutse, Andreas H Diacon, Rodney Dawson, Sunita Rehal, Gibson S Kibiki, Gavin Churchyard, 
Ian Sanne, Nyanda E Ntinginya, Lilian T Minja, Robert D Hunt, Salome Charalambous, Madeleine Hanekom, Hadija H Semvua, 
Stellah G Mpagama, Christina Manyama, Bariki Mtafya, Klaus Reither, Robert S Wallis, Amour Venter, Kim Narunsky, Anka Mekota, Sonja Henne, 
Angela Colbers, Georgette Plemper van Balen, Stephen H Gillespie, Patrick P J Phillips, Michael Hoelscher, on behalf of the PanACEA consortium† 
Summary
Background Tuberculosis is the world’s leading infectious disease killer. We aimed to identify shorter, safer drug 
regimens for the treatment of tuberculosis.
Methods We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in 
seven sites in South Africa and Tanzania, including hospitals, health centres, and clinical trial centres. Patients with newly 
diagnosed, rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio 
to receive (all orally) either 35 mg/kg rifampicin per day with 15–20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 
400 mg moxiﬂ oxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, 
or a daily standard control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15–20 mg/kg 
ethambutol). Experimental treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 
12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day. Because of the orange discoloration 
of body ﬂ uids with higher doses of rifampicin it was not possible to mask patients and clinicians to treatment allocation. 
The primary endpoint was time to culture conversion in liquid media within 12 weeks. Patients without evidence of 
rifampicin resistance on phenotypic test who took at least one dose of study treatment and had one positive culture on 
liquid or solid media before or within the ﬁ rst 2 weeks of treatment were included in the primary analysis (modiﬁ ed 
intention to treat). Time-to-event data were analysed using a Cox proportional-hazards regression model and adjusted for 
minimisation variables. The proportional hazard assumption was tested using Schoelfeld residuals, with threshold 
p<0·05 for non-proportionality. The trial is registered with ClinicalTrials.gov (NCT01785186).
Findings Between May 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to diﬀ erent treatment 
arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, 
pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, 
isoniazid, pyrazinamide, and moxiﬂ oxacin; and 123 to the control arm). Recruitment was stopped early in the arms 
containing SQ109 since prespeciﬁ ed eﬃ  cacy thresholds were not met at the planned interim analysis. Time to stable 
culture conversion in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days 
vs 62 days, adjusted hazard ratio 1·78; 95% CI 1·22–2·58, p=0·003), but not in other experimental arms. There was no 
diﬀ erence in any of the groups in time to culture conversion on solid media. 11 patients had treatment failure or recurrent 
disease during post-treatment follow-up: one in the 35 mg/kg rifampicin arm and none in the moxiﬂ oxacin arm. 45 (12%) 
of 365 patients reported grade 3–5 adverse events, with similar proportions in each arm.
Interpretation A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could 
be a promising component of future, shorter regimens. Our adaptive trial design was successfully implemented in a 
multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost.
Funding The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP), the 
German Ministry for Education and Research (BmBF), and the Medical Research Council UK (MRC).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Tuberculosis is now the leading infec tious disease killer 
worldwide. Treatment regi mens last at least 6 months, so 
shorter, safer, and more eﬀ ective regimens for drug-
sensitive tuber culosis are needed as part of the global 
strategy to eliminate the disease. 
Rifampicin is a key drug that, combined with 
pyrazinamide, reduced tuberculosis treatment from 18 
to 6 months.1,2 The standard dose of rifampicin 
(10 mg/kg) was chosen in the 1960s, primarily because 
of cost.2 However, results of several studies in mice3–6 
showed that higher doses can accelerate cure, and 
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higher doses seemed to increase sputum culture 
conversion in clinical trials.7 In a dose ranging trial,8 
35 mg/kg showed increased eﬃ  cacy and good 
tolerability when admini stered daily for 14 days. In 
another phase 2 study9 of 600 mg (10 mg/kg), 900 mg 
(15 mg/kg), and 1200 mg (20 mg/kg) rifampicin with 
standard concomitant treatment, patients showed good 
tolerability but no diﬀ erence in eﬃ  cacy in the three 
groups.
To address the challenge of choosing among the many 
potential drug combinations that should be assessed in 
phase 3 clinical trials, we adapted a multi-arm, multi-
stage trial design10 that has been used successfully in 
oncology,11 and in which multiple regimens are 
compared with a common standard regimen. Recruit-
ment to insuﬃ  ciently eﬃ  cacious regimens is 
discontinued if prespeciﬁ ed thresholds are not achieved 
to save time and resources, and to reduce the risk of 
exposing patients to an ineﬀ ective treatment. The 
objective of this approach is to generate data to select a 
regimen that might be eligible to progress to a pivotal 
phase 3 trial. We selected regimens based on literature 
and on previous studies within our consortium 
PanACEA (Pan African Con sortium for the Evaluation 
of Antituberculosis Anti biotics). Regimens assessed in 
our trial also included 300 mg SQ109 (Sequella, 
Rockville, MD), a well-tolerated drug candidate based on 
the ethylene diamine pharma copore.12,13 Moxiﬂ oxacin 
was chosen to be assessed in combination with 
20 mg/kg rifampicin. Moxiﬂ oxacin is a licensed 
antibiotic that leads to faster culture conversion when 
substituted for either isoniazid or ethambutol.14–16
We present the results of the PanACEA MAMS-TB 
trial, in which we aim to investigate four new potential 
regimens and establish a new pathway for tuberculosis 
drug regimen development.
Methods
Study design
We did a randomised, controlled, open-label, multi-arm, 
multi-stage study (MAMS) in three clinical trial sites in 
Tanzania and four trial sites in South Africa, including 
hospitals, health centres, and clinical trial units. The 
protocol was approved by independent ethics committees 
of the sponsor and the trial sites, and regulatory 
authorities of Tanzania and South Africa, and done 
according to Good Clinical Practice guidelines.17 The 
protocol is available in the appendix and panacea-tb.net.
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 Research in context
Evidence before this study
We did literature searches in PubMed, applying the Medical 
Subject Heading (MeSH) terms ‘‘tuberculosis’’; and “rifampicin 
AND dose”, “moxiﬂ oxacin”, or “SQ109”. Publications on 
pulmonary tuberculosis listed not later than April 30, 2016, in 
English, German, French, and Italian language were considered.
Pharmacokinetic studies indicate that standard dose 
(1 0mg/kg) of rifampicin often did not achieve eﬀ ective 
plasma concentrations in patients. Enhanced eﬃ  cacy of higher 
doses of rifampicin was reported in a number of animal 
studies. A systematic review on elevated doses of rifampicin 
published before 2008 identiﬁ ed 14 studies testing up to 
1200 mg of rifampicin. Despite diﬃ  culties comparing eﬃ  cacy 
outcomes across trials, there was an indication that higher 
doses were beneﬁ cial. Among 339 articles published after 
2008, a single 14-day dose-ranging study of up to 35 mg/kg 
reported a supra-proportional increase in pharmacokinetic 
parameters and good tolerability, with a suggestion of 
enhanced early bactericidal activity. 43 publications on SQ109 
were identiﬁ ed. A mouse study reported improved eﬃ  cacy when 
SQ109 replaced ethambutol, but with a delayed onset of several 
weeks in reduction of lung and spleen colony-forming units. One 
14-day phase 1 and one phase 2a study reported good 
tolerability, but absence of early bactericidal activity during the 
14-day phase 2a study duration. A meta-analysis of 
moxiﬂ oxacin trials concluded that this drug added to the 
bactericidal activity of the regimen when it replaced 
ethambutol or isoniazid, but this was not enough to shorten 
treatment duration from 6 to 4 months.
Added value of this study
This study showed that 35 mg/kg rifampicin given over 
12 weeks was safe and shortened the time to stable culture 
conversion from 62 to 48 days, showing the potential for an 
enhanced regimen. The other experimental arms, including 
various combinations of 10 mg/kg or 20 mg/kg of rifampicin, 
moxiﬂ oxacin, and SQ109, did not achieve signiﬁ cant 
improvements over the control arm. Taking all the data into 
consideration, this study supports that rifampicin given at 
35 mg/kg is likely to improve treatment outcome. To our 
knowledge, this is the ﬁ rst time that a multi-arm adaptive 
trial design was successfully implemented in a multi-centre 
study in a high tuberculosis burden setting. This approach 
might accelerate tuberculosis regimen development at a 
reduced cost.
Implications of all the available evidence
Our study substantiated that an increase in rifampicin dose 
could improve the clearance of bacteria in patients with 
pulmonary tuberculosis without an increase in associated 
adverse events. The scale of the improvement shown in this 
study of 35 mg/kg rifampicin administered orally could translate 
to improved clinical outcomes. Smaller increases in rifampicin 
doses did not have this eﬀ ect and suggest that future pivotal 
phase 3 studies should be done with at least 35 mg/kg. 
The combination of moxiﬂ oxacin and 20 mg/kg rifampicin had 
a modest eﬀ ect on bacterial clearance. This combination could 
be improved by increasing the dose of moxiﬂ oxacin to 
overcome induction of its metabolism by rifampicin.
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Patients
Eligible patients were aged 18 years or older, weighed 
35–90 kg, had newly diagnosed, previously untreated 
pulmonary tuberculosis conﬁ rmed to be rifampicin 
sensitive by Xpert MTB/RIF, and positive smear 
microscopy of at least 1+ on the IUATLD/WHO scale. 
Patients with HIV were eligible if their CD4 count was 
greater than 200 cells per μL, and where local ethics 
committees agreed that antiretroviral treatment could be 
safely withheld until study week 12. Female patients were 
excluded if they were pregnant or breastfeeding. Patients 
were excluded if they received or required therapy 
expected to prolong the QT interval in electrocardiogram 
(ECG), or alter cytochrome P450 enzyme activity with 
potential eﬀ ects on SQ109 metabolism (appendix p 7). 
Patients were recruited by invitation if diagnosed with 
tuberculosis in the public health system and included if 
they gave written informed consent
124 assigned to control arm
123 started treatment
 1 randomised in error
117 completed 6-month follow-up
 6 withdrew
123 included in modified ITT analysis
105 (85%) completed 12-month 
  follow-up 
  6 only attended 9 month visit
 12 never contacted
 4 withdrew
 6 lost to follow-up before 
   6 months
 2 not contacted in error
1 death
2 recurrences
1 recurrence diagnosed at 
  non-study health centre on 
  GeneXpert without culture 
  confirmation
57 assigned to RIF20QHZ arm
57 started treatment
52 completed 6-month follow-up
 5 withdrew
56 included in modified ITT analysis
 1 rifampicin resistant at baseline
50 (89%) completed 12-month 
  follow-up 
  2 only attended 9 month visit
 4 never contacted
 1 withdrew
 3 lost to follow-up before 
  6 months
3 recurrences
1 recurrence diagnosed at 
  non-study health centre on 
  GeneXpert without culture 
  confirmation
60 assigned to RIFQHZ arm
59 started treatment
 1 randomised in error
53 completed 6-month follow-up
 6 withdrew
58 included in modified ITT analysis
 1 rifampicin resistant at baseline
45 (78%) completed 12-month 
  follow-up 
  3 only attended 9 month visit
 10 never contacted
  2 withdrew
 6 lost to follow-up before 
  6 months
 1 late exclusion in study
 1 positive for MDR TB
1 recurrence
1 treatment failure, developed 
  MDR TB, was treated and cured
1 recurrence diagnosed at 
  non-study health centre on 
  acid-fast bacilli smear without
   culture confirmation
64 assigned to RIF35HZE arm
63 started treatment
 1 randomised in error
57 completed 6-month follow-up
 1 died
 5 withdrew
63 included in modified ITT analysis
54 (86%) completed 12-month 
  follow-up 
  1 only attended 9 month visit
 8 never contacted
 3 withdrew
 4 lost to follow-up before 
  6 months
 1 <1 month on treatment
0 recurrences
63 assigned to RIF20MHZ
63 started treatment
58 completed 6-month follow-up
 5 withdrew
63 included in modified ITT analysis
52 (83%) completed 12-month 
  follow-up 
  3 only attended 9 month visit
 8 never contacted
 2 withdrew
 3 lost to follow-up before 
  6 months
 1 not contacted in error
 2 <1 month on treatment
0 recurrences
632 patients screened
264 excluded
 63 inadmissible lab results
 47 inadequate sputum bacterial load
 42 on ART (South Africa) or HIV positive (Tanzania)
 22 clinically relevant medical conditions
 21 failed drug screening
 14 drug resistance
 9 withdrew consent
 7 inadmissible ECG
 6 poor general condition
 5 low CD4 count
 28 other
Figure 1: Trial proﬁ le
Recruitment to RIFQHZ arm and RIF20QHZ arm was stopped early following the ﬁ rst interim analysed. Three patients who were randomised in error were not started on treatment and not retained in 
follow-up. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, ethambutol. RIFQHZ=rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, isoniazid, 
pyrazinamide, SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, moxiﬂ oxacin 400 mg. ITT=intention-to-treat. MDR TB=multi-drug resistant tuberculosis. Doses of concomitant 
drugs are detailed in Procedures.
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Randomisation and masking
Patients were randomly assigned centrally using a web-
based computerised algorithm, developed and main-
tained by the MRC Clinical Trials Unit. We used a 
random element of 80% for minimisation, stratiﬁ ed on 
study site, baseline bacterial load reported by Xpert 
MTB/RIF (high vs low; high is <16 cycle threshold), and 
HIV status. Eligible patients were assigned in a 1:1:1:1:2 
ratio to one of four daily experimental regimens or a 
daily control regimen. Because of the orange dis-
coloration of body ﬂ uids with higher doses of rifampicin 
it was not possible to mask patients and clinicians to 
treatment allocation. However, all laboratory assess-
ments were done blind to treatment allocation and only 
the independent data monitoring committee (IDMC) 
and the trial statisticians saw data aggregated by 
treatment arm during the trial.
Procedures
All drugs were oral, given once daily, 7 days per week. 
Control treatment consisted of standard dose rifampicin 
(10 mg/kg [range 8·1–11·8 mg/kg]), isoniazid 
(5 mg/kg [4·1–5·9 mg/kg]), pyrazinamide (25 mg/kg 
[21·6–31·6 mg/kg]), and ethambutol (15–20 mg/kg 
[14·9–21·7 mg/kg]) for 8 weeks, followed by 18 weeks of 
standard dose rifampicin and isoniazid. Experimental 
treatments consisted of rifampicin 35 mg/kg, plus 
standard dose isoniazid, pyrazinamide, and ethambutol 
(arm RIF35HZE); rifampicin 10 mg/kg, standard dose 
isoniazid and pyrazinamide, and SQ109 300 mg (arm 
RIFQHZ); rifampicin 20 mg/kg, standard dose isoniazid 
and pyrazinamide, and SQ109 300 mg (arm RIF20QHZ); 
or rifampicin 20 mg/kg, standard dose isoniazid and 
pyrazinamide, and moxiﬂ oxacin 400 mg (arm 
RIF20MHZ). Experimental treatment was given for 
12 weeks, followed by 14 weeks of standard dose isoniazid 
and rifampicin. Pyridoxine (vitamin B6, 25 mg) was 
given in the morning to all patients throughout the trial. 
The control regimen was weight banded according to the 
South African tuberculosis treatment guidelines18 and 
implemented in both partici pating countries (appendix 
p 10). Higher doses of rifampicin were adapted to these 
weight bands (appendix). All drugs were self-
administered except for days of clinic visits, where 
administration was directly observed. Participants were 
advised to take their drugs in the morning after a light 
breakfast and with a glass of water.
The primary study objective was to assess whether the 
experimental regimens, given for 12 weeks, resulted in 
shorter time to sputum culture conversion in liquid 
media compared with standard treatment. Patients were 
seen once per week up to week 12, and at weeks 14, 17, 22, 
and 26 after start of treatment. Sputum for smear and 
culture was taken 2 days before start of treatment, and at 
all visits. Samples were processed and cultured in liquid 
broth medium culture according to the myco bacteria 
growth indicator tube (Bactec MGIT960) system, on 
Löwenstein-Jensen (LJ) solid medium; and sensitivity to 
isoniazid, rifampicin, and ethambutol was assessed by 
liquid culture susceptibility testing (SIRE) at baseline 
and positive cultures after week 12, following the 
procedures described previously.15 Safety assessments 
included physical examination and vital signs. Liver 
func tion tests, lipase, electrolytes, glucose, and haema-
tology were done at screening and treatment weeks 1, 2, 
4, 6, 9, 12, and 14. Coagulation assessments were done at 
screening and at week 2, and ECGs at screening, 
baseline, and at week 1 and 2. The Friderica formula was 
used for heart rate correction of QT.19 All laboratory staﬀ  
and ECG analysts were blinded to treatment allocation. 
Post-treatment follow-up was introduced during 
Control RIF35HZE RIFQHZ RIF20QHZ RIF20MHZ Total
Number 
randomised*
123 63 59 57 63 365
Age (years) 34 (26–41) 33 (23–40) 32 (25–40) 34 (27–41) 31 (24–38) 33 (26–40)
Male 94 (76%) 42 (67%) 38 (64%) 45 (79%) 39 (62%) 258 (71%)
Weight (Kg) 54 (49–59) 52 (47–58) 53 (47–57) 53 (49–56) 52 (48–61) 53 (49–58)
HIV positive 9 (7%) 4 (6%) 5 (8%) 3 (5%) 3 (5%) 24 (7%)
Ethnicity
Black 101 (82%) 51 (81%) 50 (85%) 50 (88%) 48 (76%) 300 (82%)
White 0 (0%) 1 (2%) 0 (0%) 1 (2%) 0 (0%) 2 (1%)
Mixed 19 (15%) 11 (17%) 9 (15%) 6 (11%) 15 (24%) 60 (16%)
Other 3 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (1%)
Xpert MTB/RIF 
cycle threshold
16 (14–19) 17 (14–20) 17 (14–19) 16 (14–18) 16 (14–19) 16 (14–19)
Phenotypic resistance to rifampicin
Resistant 0 (0%) 0 (0%) 1 (2%) 1 (2%) 0 (0%) 2 (1%)
Sensitive 112 (91%) 59 (94%) 54 (92%) 53 (93%) 56 (89%) 334 (92%)
Missing 11 (9%) 4 (6%) 4 (7%) 3 (5%) 7 (11%) 29 (8%)
Phenotypic resistance to isoniazid
Resistant 3 (2%) 0 (0%) 3 (5%) 1 (2%) 1 (2%) 8 (2%)
Sensitive 109 (89%) 59 (94%) 52 (88%) 53 (93%) 55 (87%) 328 (90%)
Missing 11 (9%) 4 (6%) 4 (7%) 3 (5%) 7 (11%) 29 (8%)
Phenotypic resistance to moxiﬂ oxacin
Resistant 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Sensitive 115 (93%) 59 (94%) 55 (93%) 54 (95%) 56 (89%) 339 (93%)
Missing 8 (7%) 4 (6%) 4 (7%) 3 (5%) 7 (11%) 26 (7%)
Phenotypic resistance to ethambutol
Resistant 0 (0%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 1 (0%)
Sensitive 112 (91%) 59 (94%) 55 (93%) 53 (93%) 56 (89%) 335 (92%)
Missing 11 (9%) 4 (6%) 4 (7%) 3 (5%) 7 (11%) 29 (8%)
Phenotypic resistance to pyrazinamide
Resistant 4 (3%) 2 (3%) 2 (3%) 0 (0%) 4 (6%) 12 (3%)
Sensitive 110 (89%) 57 (90%) 53 (90%) 55 (96%) 53 (84%) 328 (90%)
Missing 9 (7%) 4 (6%) 4 (7%) 2 (4%) 6 (10%) 25 (7%)
*An additional three patients were randomised in error and did not start treatment or remain in follow-up and are 
therefore not included in this table. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, ethambutol. RIFQHZ 
=rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, 
SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, moxiﬂ oxacin 400mg. Data are median (IQR) 
or n (%) unless otherwise speciﬁ ed. Doses of concomitant drugs are detailed in Procedures. 
Table 1: Baseline characteristics by arm 
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enrolment, following the IDMC review of the results of 
the ﬁ rst interim analysis. Follow-up was done at 3 months 
and 6 months after end of treatment by telephone, and 
patients were invited to attend the clinic for assessment 
if feeling unwell.
An electronic source documentation system (Clinical 
Ink, Winston Salem, NC), was used for clinical and 
laboratory data capture. All data were stored in a central 
study database to facilitate regular monitoring of data 
quality and completeness.
Outcomes
The primary endpoint was time from treatment initiation 
to the ﬁ rst of two consecutive negative once-weekly 
sputum cultures without an intervening positive culture 
in liquid media, up to 12 weeks. Secondary endpoints 
were time to ﬁ rst negative culture in liquid and solid 
media, the proportion of patients converting to negative 
sputum culture in liquid and solid media at each time-
point during treatment, rate of change in time to positivity 
in liquid culture and frequency of treatment failures or 
development of drug resistance in the diﬀ erent experi-
mental arms, and safety. Modelling of rate of change in 
time to positivity in liquid culture is ongoing and will be 
reported more fully in a subsequent modelling paper.
Mycobacteriology endpoints were acquisition of 
resistance against rifampicin, pyrazinamide, isoniazid, 
ethambutol, and moxiﬂ oxacin during therapy. Minimum 
inhibitory concentrations and their change over treat-
ment, and strain typing by genome sequencing that 
allows true relapse to be distinguished from reinfection 
are other endpoints that are being assessed and will be 
reported in a subsequent paper.
Adverse events were registered according to the 
Common Terminology Criteria for Adverse Events 4.03 
(CTCAE).20 An adverse event was classiﬁ ed as serious if it 
led to death, permanent or signiﬁ cant disability, was a 
congenital anomaly or birth defect, was life threatening, 
or required hospital admission for management. Safety 
and eﬃ  cacy results were reviewed by the IDMC at 
6-monthly intervals during the trial. A trial steering 
committee with independent chair and majority 
supervised the conduct of the trial and made decisions 
following recommendations from the IDMC.
Pharmacokinetics sub-study
20 patients allocated to each study arm, divided equally 
between the South African and Tanzanian sites, were 
enrolled into a pharmacokinetics sub-study where blood 
was taken at treatment week 4. A full description of the 
pharmacokinetic sub-study is provided in the appendix 
(pp 13–15).
Statistical analysis
We assumed culture conversion of 85% by 12 weeks in the 
control arm14 and a 5% loss to follow-up, which meant that 
124 patients in the control arm and 62 in the experimental 
arm would be adequate to detect a hazard ratio of 1·8 with 
90% power and a two-sided type I error of 5% for each 
pairwise comparison (a total of 372 patients). We selected a 
hazard ratio (HR) of 1·8 as a criterion to indicate potential 
for treatment shortening, since this represented an increase 
over the 1·68 HR obtained in the moxiﬂ oxacin-containing 
phase 2 trial that led to the phase 3 REMoxTB trial.14,18
Up to two interim IDMC analyses were planned after 
28 and then 50 patients from the control arm had 
Control RIF35HZE RIFQHZ RIF20QHZ RIF20MHZ Total
Total in analysis (mITT) 123 63 58 56 63 363
Number of culture conversions during 26-week 
follow-up (MGIT culture)
101 (82%) 51 (81%) 44 (76%) 48 (86%) 52 (83%) 296 (82%)
Number of culture conversions during 26-week 
follow-up (solid culture)
117 (95%) 59 (94%) 59 (97%) 54 (96%) 59 (94%) 345 (95%)
Primary analysis to 12 weeks (MGIT culture)
Cumulative probability of culture conversion 
by 12 weeks
70·1% 79·9% 65·2% 58·6% 78·7% ..
Median time to culture conversion (IQR) 62 (41–83) 48 (34–69) 63 (48–83) 66 (41–83) 55 (41–69) ..
Adjusted hazard ratio (95%)* .. 1·78 (1·22–2·58) p=0·003 0·85 (0·57–1·27) p=0·42 0·76 (0·50–1·17) p=0·21 1·42 (0·98–2·05) p=0·07 ..
Hazard ratio (95%), unadjusted .. 1·46 (1·02–2·11) p=0·04 0·90 (0·60–1·34) p=0·60 0·76 (0·50–1·16) p=0·21 1·34 (0·93–1·93) p=0·12 ..
Solid LJ culture to 12 weeks (secondary)
Cumulative probability of culture conversion 
by 12 weeks
97·3% 100·0% 94·4% 94·2% 98·0% ..
Median time to culture conversion (IQR) 27 (13–48) 20 (7–41) 20 (7–48) 20 (11–44) 29 (20–48) ..
Adjusted hazard ratio (95% CI)* .. 1·23 (0·89–1·69) p=0·21 0·91 (0·66–1·27) p=0·58 0·98 (0·70–1·38) p=0·93 0·77 (0·56–1·06) p=0·11 ..
Unadjusted hazard ratio (95% CI) .. 1·28 (0·93–1·75) p=0·13 1·02 (0·73–1·41) p=0·92 1·06 (0·76–1·47) p=0·74 0·90 (0·65–1·23) p=0·50 ..
LJ=Löwenstein-Jensen. MGIT=mycobacteria growth indicator tube. mITT=modiﬁ ed intention to treat. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, ethambutol. RIFQHZ=rifampicin 10 mg/kg, 
isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, moxiﬂ oxacin 400 mg. Doses of 
concomitant drugs are detailed in Procedures. *Analysis adjusted for HIV status, GeneXpert cycle threshold (<16, ≥16), and site. MGIT analyses also adjusted for baseline time to positivity.
Table 2: Summary of analyses of time to culture conversion in MGIT culture (primary) and on solid LJ culture (secondary) to 12 weeks 
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achieved stable culture conversion endpoint. Recruitment 
was to be terminated in experimental arms with HR less 
than 1·09 (ﬁ rst interim) or less than 1·23 (second 
interim). The probability of continuing an eﬃ  cacious 
arm at each interim analysis—the stage-wise power—
was 0·95, and the probability of not dropping an 
ineﬃ  cacious arm—the stage-wise type I error—was 0·4 
(ﬁ rst interim) and 0·2 (second interim).
Patients without evidence of rifampicin resistance on 
phenotypic test who took at least one dose of study 
treatment and had one positive culture on liquid or solid 
media before or within the ﬁ rst 2 weeks of treatment 
were included in the primary analysis population 
(a modiﬁ ed intention-to-treat [ITT] population). In 
secondary analyses, the primary endpoint was also 
analysed on an ITT population (all randomly assigned 
patients) and a per-protocol population (PP, the modiﬁ ed 
ITT population, excluding randomly assigned patients 
that did not meet the eligibility criteria and patients that 
missed 21 or more doses of their allocated treatment in 
the ﬁ rst 12 weeks). The modiﬁ ed ITT population was not 
included in the original trial protocol, but was included 
as the primary analysis population in the statistical 
analysis plan before any interim analyses to allow 
comparison with other tuberculosis trials. Including 
patients without culture-conﬁ rmed disease (ITT) or 
excluding patients based on post-randomisation data 
(PP) can introduce bias, and therefore the modiﬁ ed ITT 
population was preferred. Time-to-event data were 
analysed using a Cox proportional-hazards regression 
model and adjusted for minimisation variables (HIV 
status, Xpert MTB/RIF cycle threshold, centre) and for 
the baseline liquid culture bacterial load measurement, 
time to positivity (mean of pre-treatment cultures) for 
analyses of liquid culture data. Log-rank statistics were 
also calculated for time-to-event data, both unstratiﬁ ed 
and stratiﬁ ed by minimisation variables. The 
proportional-hazards assumption was tested using 
Schoelfeld residuals, with p<0·05 evidence for non-
proportionality. Details of secondary outcomes and 
sensitivity analyses are described in the appendix. Post-
hoc analyses for time to stable culture conversion to 
8 weeks on liquid and solid media that were not 
prespeciﬁ ed in the statistical analysis plan were done for 
comparability with previous phase 2 studies.
To assess safety, the proportion of adverse events and 
the proportion of adverse events assessed by the 
investigators as probably related or related to treatment 
was presented by group. Data were analysed using Stata 
version 13.1 (StataCorp, College Station, Texas).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Sequella, Inc provided SQ109. Sequella had no role in 
study design, data collection, data analysis, and data 
interpretation; they reviewed the paper and made 
comments.
Results
Between May 7, 2013, and March 25, 2014, 632 patients 
were screened and 365 were enrolled in Tanzania (51 in 
Moshi, 52 in Mbeya, and 53 in Bagamoyo) and South 
Africa (88 in Cape Town, 48 in Stellenbosch, 30 in 
Johannesburg, and 43 in Tembisa). Three additional 
patients were randomised in error and were not started 
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Figure 2: Kaplan-Meier curve for time to culture conversion
(A) Time to culture conversion in liquid MGIT media. (B) Time to culture conversion on solid Löwenstein-Jensen 
media. MGIT=mycobacteria growth indicator tube. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, 
ethambutol. RIFQHZ=rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, 
isoniazid, pyrazinamide, SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, moxiﬂ oxacin 
400 mg. Doses of concomitant drugs are detailed in Procedures. Dashed vertical line refers to the week 8 time-point 
(cutoﬀ  in post-hoc analysis). Solid vertical line refers to the week 12 time-point (cutoﬀ  in primary analysis). 
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on treatment and not continued in follow-up (ﬁ gure 1). 
Recruitment to the RIFQHZ and RIF20QHZ arms was 
terminated following the recommendation from the 
IDMC after review of results from the ﬁ rst scheduled 
interim analysis; however, enrolled patients continued 
on allocated treatment. Recruitment to all other arms 
continued until the target sample sizes in each arm had 
been reached. Recruitment was completed before the 
scheduled second interim analysis, which was therefore 
not done.
Baseline characteristics were similar between arms 
(table 1). Two patients were rifampicin resistant on 
phenotypic tests and were excluded from the modiﬁ ed 
ITT analysis population.
Patients achieved faster stable culture conversion in 
MGIT on the RIF35HZE arm than on the control arm, with 
a median time to stable culture conversion of 48 days 
compared with 62 days (adjusted HR 1·78, 95% CI 
1·22–2·58; p=0·003, table 2, ﬁ gure 2). HR was smaller in 
the unadjusted analysis (HR 1·46, 95% CI 1·02–2·11; 
p=0·04). None of the other arms reported signiﬁ cantly 
faster culture conversion than control, with the largest 
eﬀ ect seen in the RIF20MHZ arm (adjusted HR 1·42, 
95% CI 0·98–2·05; p=0·07). The cumulative proportion of 
patients achieving the primary endpoint of culture 
conversion in liquid media at week 12 (using the 
Kaplan-Meier estimator) was 70·1% (control), 79·9% 
(RIF35HZE), 65·2% (RIFQHZ), 58·6% (RIF20QHZ), and 
78·7% (RIF20MHZ).
Time to culture conversion on solid media did not diﬀ er 
signiﬁ cantly between any of the arms and the control 
arm. In the post-hoc analysis for comparability with 
previous tuberculosis phase 2 trials14,21 at 8 weeks, HR for 
the primary endpoint on liquid culture was higher for 
RIF35HZE (adjusted HR 2·06, 95% CI 1·26–3·38; 
p=0·004) and for RIF20MHZ (1·67, 1·01–2·67; p=0·05, 
table 3). None of the arms reported signiﬁ cantly faster 
time to culture conversion than the control arm on solid 
media when data were censored at 8 weeks. To understand 
the diﬀ erences in results between solid and liquid media, 
we did a further post-hoc analysis of time to culture 
conversion by excluding patients without a positive 
culture on solid media before or within the 2 weeks of 
randomisation; this analysis gave HRs that were 
marginally closer than those in liquid media, but 
diﬀ erences between solid and liquid media remained 
(table 3). Results of further sensitivity analysis for the 
primary outcome and the secondary outcomes time to 
ﬁ rst negative culture in liquid and solid media and 
proportion of patients converting to negative sputum 
culture in liquid and solid media at each timepoint during 
treatment are presented in the appendix (pp 16–18). 
Control RIF35HZE RIFQHZ RIF20QHZ RIF20MHZ
MGIT culture censored at 8 weeks (post hoc)
Cumulative probability of 
culture conversion by 8 weeks
32% 49% 34·5% 27·8% 46·2%
Adjusted hazard ratio (95% CI)* .. 2·06 (1·26–3·38) p=0·004 1·04 (0·59–1·81) p=0·90 0·91 (0·49–1·67) p=0·76 1·67 (1·01–2·67) p=0·05
Unadjusted hazard ratio (95% CI) .. 1·73 (1·07–2·82) p=0·03 1·07 (0·62–1·86) p=0·81 0·87 (0·48–1·58) p=0·64 1·47 (0·90–2·40) p=0·13
Solid LJ culture censored at 8 weeks (post hoc)
Cumulative probability of 
culture conversion by 8 weeks
80·9% 88·0% 83·9% 82·6% 82·7%
Adjusted hazard ratio (95% CI)* .. 1·17 (0·83–1·64) 1·00 (0·70–1·42) 1·06 (0·74–1·52) 0·76 (0·54–1·07)
Adjusted log-rank test* .. p=0·38 p=1·00 p=0·75 p=0·12
Unadjusted hazard ratio 
(95% CI)
.. 1·24 (0·88–1·73) 1·09 (0·77–1·55) 1·12 (0·79–1·60) 0·88 (0·63–1·24)
Unadjusted log-rank test .. p=0·22 p=0·62 p=0·53 p=0·48
Solid LJ culture censored at 12 weeks excluding without a positive culture on LJ solid media before or within the 2 weeks of randomisation (post hoc)
Number in analysis (total=297) 101 46 45 47 58
Cumulative probability of 
culture conversion by 8 weeks
96·7% 100·0% 92·8% 93·3% 97·8%
Adjusted hazard ratio (95% CI)* .. 1·37 (0·95–1·99) 0·84 (0·58–1·23) 1·00 (0·69–1·45) 0·88 (0·62–1·24)
Adjusted log-rank test* .. p=0·19 p=0·78 p=0·62 p=0·37
Unadjusted hazard ratio 
(95% CI)
.. 1·37 (0·95–1·98) 0·92 (0·64–1·34) 1·05 (0·73–1·51) 0·95 (0·67–1·33)
Log-rank test, unadjusted .. p=0·07 p=0·65 p=0·76 p=0·73
LJ=Löwenstein-Jensen. MGIT=mycobacteria growth indicator tube. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, ethambutol. RIFQHZ=rifampicin 10 mg/kg, 
isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, 
moxiﬂ oxacin 400 mg. Doses of concomitant drugs are detailed in Procedures. *Analysis adjusted for HIV status, GeneXpert cycle threshold (<16, ≥16), and site. MGIT analyses 
also adjusted for baseline time to positivity.
Table 3: Summary of analyses of time to culture conversion in MGIT and on LJ culture to 8 weeks (post hoc), and on LJ culture excluding patients without 
positive LJ at baseline (post hoc)
For an interactive graph on 
sensitivity analysis see 
http://www.ctu.mrc.ac.uk/
resources/panacea/mamstb/
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One patient with baseline isoniazid mono-resistance 
treated with RIFQHZ acquired rifampicin and 
pyrazinamide resistance and was classiﬁ ed as treatment 
failure at week 17. The patient received appropriate 
treatment for multi-drug resistant tuberculosis and was 
reported cured after follow-up. Acquired drug resistance 
was not seen in any other patients. Seven patients were 
diagnosed with recurrent disease at 12 months after 
randomisation, and three more were identiﬁ ed by non-
study health facilities without culture conﬁ rmation (one 
by smear and two by Xpert MTB/RIF; ﬁ gure 1). Of these 
11 unfavourable outcomes, only one occurred on the 
RIF35HZE arm and none on the RIF20MHZ arm, and all 
had longer time to conversion to negative culture in 
liquid media (median 97 days vs 62 days in those without 
failure or recurrence, p=0·013), but not on solid media 
(median 27 days vs 27 days, p=0·157).
45 patients reported at least one grade 3, 4, or 5 adverse 
event with similar proportions in each arm (table 4). 
There was one death during the trial, a patient on the 
RIF35HZE arm who died 13 weeks after experimental 
treatment was completed, near the end of the con-
tinuation phase, and who complained of sudden onset 
chest pain hours before death. This death was unlikely 
to be related to the higher dose of rifampicin. One 
patient in the control arm completed treatment 
successfully but later relapsed and died from underlying 
pneumoconiosis, related to work as a miner in Tanzania. 
Eight patients with hepatic adverse events fulﬁ lled the 
criteria for treatment interruption (table 4). Investigators 
opted for treatment interruption in two additional cases 
of grade 2 elevated transaminases in arm RIF35HZE, in 
whom the protocol toxicity criteria for interruption were 
not fulﬁ lled. Five patients were restarted on study 
treatment, which was tolerated by three. No QTcF 
interval of more than 480 ms was recorded during the 
study. Further details of adverse events are in the 
appendix (p 12).
Increasing the rifampicin dose from 10 to 35 mg/kg 
resulted in a more than proportional increase in the 
geometric mean area under the curve (AUC)0–24h and 
maximum concentration (Cmax) of rifampicin [appendix, 
pp 12–15, 21]. No signiﬁ cant diﬀ erences in isoniazid, 
pyrazinamide, or ethambutol exposure were found 
between standard and higher dose rifampicin arms, 
indicating that higher doses of rifampicin do not aﬀ ect 
the exposures to these drugs. Tanzanians had a lower 
rifampicin AUC0–24h than South Africans in the RIF35HZE 
arm (geometric means 145 and 206 h × mg/L, 11 vs 
9 patients, p=0·001). Pyrazinamide AUC0–24h values were 
also lower in Tanzanians than South Africans (317 and 
360 h × mg/L, 94 patients, p=0·02). Plasma con-
centrations of SQ109 in the study are not yet available, a 
pharmacokinetic-pharmacodynamic analysis is ongoing, 
and will be reported separately.
Discussion
Our study shows that a regimen including rifampicin 
35 mg/kg resulted in signiﬁ cantly faster liquid culture 
conversion by 12 weeks. Previous tuberculosis trials have 
used culture conversion at 8 weeks, and the 8-week 
adjusted HR of 2·06 in our trial is the highest reported 
for any tuberculosis regimen; HRs from other trials 
include 1·68 for pretomanid,21 1·52 for gatiﬂ oxacin,14 and 
1·68 for moxiﬂ oxacin.14 Only a study22 of high dose 
rifapentine reported similar activity in terms of 
increasing the proportion of patients with sputum 
culture conversion at 8 weeks. Culture con version rates 
in our study at weeks 12 and 26 were lower than in 
comparable trials. One patient had treatment failure with 
persistent positive cultures, but the others did not achieve 
the endpoint because of the stringent deﬁ nition used, 
Control RIF35HZE RIFQHZ RIF20QHZ RIF20MHZ Total
Total in safety analysis 123 63 59 57 63 365
Patients with at least one AE 92 (75%) 53 (84%) 49 (83%) 42 (74%) 49 (78%) 285 (78%)
Patients with at least one grade 3, 4, or 5 AE 13 (11%) 9 (14%) 7 (12%) 7 (12%) 9 (14%) 45 (12%)
Patients with at least one grade 3, 4, or 5 AE considered probably 
related or related
1 (1%) 3 (5%) 0 0 4 (6%) 8 (2%)
Patients with at least one serious AE 6 (5%) 4 (6%) 4 (7%) 5 (9%) 4 (6%) 23 (6%)
Deaths 0 1 0 0 0 1
Total number of patients with treatment changed due to hepatic AE 2 (2%) 5 (8%) 0 (0%) 3 (5%) 0 10 (3%)
Number of patients with treatment changed due to hepatic 
AE—symptomatic or meeting protocol criteria*
2 (2%) 3 (5%) 0 (0%) 3 (5%) 0 8 (2%)
Treatment changed due to hepatic AE—not fulﬁ lling protocol 
criteria and not being symptomatic*
0 2 (3%) 0 0 0 (1%)
AE=adverse event. AST=aspartate aminotransferase. ALT=alanine transaminase. RIF35HZE=rifampicin 35 mg/kg, isoniazid, pyrazinamide, ethambutol. RIFQHZ=rifampicin 
10 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20QHZ=rifampicin 20 mg/kg, isoniazid, pyrazinamide, SQ109 300 mg. RIF20MHZ=rifampicin 20 mg/kg, isoniazid, 
pyrazinamide, moxiﬂ oxacin 400 mg.  Doses of concomitant drugs are detailed in Procedures. *Protocol criteria for treatment interruption due to hepatic AE: elevation of AST 
or ALT more than three times, but less than ﬁ ve times the upper limit of normal, with associated symptoms or elevation of AST or ALT more than ﬁ ve times the upper limit of 
normal irrespective of the presence of symptoms.
Table 4: Summary of adverse events 
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which requires two negative cultures from successive 
visits, and is susceptible to missing culture results by 
contamination or missing sample.
None of the other arms in our study resulted in faster 
culture conversion in liquid or on solid culture 
compared with control. Although RIF20MHZ was the 
best of 20 mg/kg rifampicin regimens, it was not better 
than moxiﬂ oxacin containing regimens with standard 
dose rifampicin reported previously.14,15 This could be 
due to relatively low exposure to moxiﬂ oxacin in our 
cohort, considering that moxiﬂ oxacin is metabolised 
by the phase 2 metabolising enzymes uridine 
diphosphate glucurono syltransferase and sulpho-
transferase. Rifampicin is known to induce such 
phase 2 metabolic enzymes and it has been shown that 
rifampicin decreases the AUC of moxiﬂ oxacin by 
approximately 30%.23 The results in the RIF20MHZ arm 
suggest that 20 mg/kg rifampicin does not result in 
enhanced eﬃ  cacy. SQ109 did not reach the prespeciﬁ ed 
HR in the dose and combinations used. This drug is 
metabolised by cytochrome P450 iso-enzymes CYP2D6 
and CYP2C19, and at least CYP2C19 can be induced by 
rifampicin. We have previously shown that rifampicin 
decreases exposure to SQ109 administered in a 150 mg 
daily dose, but a higher daily dose of 300 mg SQ109, as 
used in our study, outweighed this inductive eﬀ ect of 
rifampicin.13
Clinical outcome was assessed at 12 months post 
randomisation (6 months after completion of treatment) 
and recurrence rates were similar between regimens.
Faster conversion in the RIF35HZE arm was only seen 
with liquid but not with solid culture, unlike a large trial 
assessing moxiﬂ oxacin regimens where the culture 
conversion results were the same on liquid and solid 
media.15 Rifampicin is considered to be eﬀ ective not only 
on actively replicating but also on persisting, non-
replicating bacterial phenotypes that are drug tolerant.24 
Incomplete killing of such bacilli is one of the proposed 
reasons for relapse after treatment completion25 as is 
poor penetration to the site of infection.26 Higher doses of 
rifampicin seem to more eﬀ ectively kill this sub-
population in experimental models4,24 and in human 
beings.27,28 Since liquid media, unlike solid media, detect 
such bacilli,29 we believe that the higher eﬃ  cacy of 
RIF35HZE seen in liquid media represents increased 
activity of this regimen on this bacterial phenotype. The 
relevance of the liquid media endpoint is further 
supported by the fact that patients with treatment failure 
or recurrent disease had later culture conversion on 
liquid media, but not on solid media (although numbers 
were small).
Increasing the dose of rifampicin from 10 to 35 mg/kg 
resulted in a more than proportional increase in 
exposure to rifampicin, which is in agreement with 
previous data30 and with more recent pharmacokinetic 
results from our rifampicin dose ranging trial.8 The 
response associated with higher doses and exposures to 
rifampicin is also in agreement with in-vitro, infected 
macrophage, and in-vivo murine data that showed an 
increased bactericidal eﬀ ect and shortening of 
treatment duration once the steep part of the rifampicin 
dose–exposure-response curve is reached.3,6 In this 
respect, the 35 mg/kg rifampicin regimen is promising 
but might not yet be optimal. Our ongoing phase 2a 
dose escalating study indicates that a higher dose of 
40 mg/kg is also safe and well tolerated.8,9 The 
rifampicin dose might yet be increased safely upon the 
human dose–exposure-response curve, which could aid 
treatment shortening and reduce the risk of rifampicin 
resistance for individuals with lower drug exposures.31 
Our data bring into question the utility of testing 
regimens with only 20 mg/kg rifampicin,9 suggesting 
that they are not likely to provide signiﬁ cant beneﬁ t or 
treatment shortening. A trial32 from Vietnam in 
tuberculosis meningitis did not ﬁ nd a reduction in 
mortality with a regimen containing 15 mg/kg oral 
rifampicin.32 A higher dose and exposure to rifampicin 
would also lessen the relevance of the wide inter-
individual variability in exposure to rifampicin as 
observed in this study. Higher AUCs were observed in 
South Africa than in Tanzania in the 35 mg/kg arm, 
possibly associated with inter-ethnic diﬀ erences in 
genetic polymorphisms of genes encoding for drug 
transporters or enzymes involved in the metabolism of 
rifampicin.33
The advantage of the concept of high dose rifampicin is 
that the drug is widely available at low cost and 
implementation could take place broadly and quickly. 
A larger pill burden is a potential disadvantage, as 
available rifampicin formulations are not adapted to the 
higher doses. After deﬁ ning the optimal dose of 
rifampicin new formulations would need to be developed 
in ﬁ xed dose combinations with companion drugs.
Experimental arms had similar safety proﬁ les to the 
control arm. Treatment interruptions due to hepatic 
events were few. Although more interruptions occurred 
in the RIF35HZE arm, in two instances the severity was 
less than speciﬁ ed by the protocol, and since clinicians 
were not blinded to treatment allocation this might have 
inﬂ uenced the decision to stop treatment.
Our study was, to our knowledge, the ﬁ rst multi-arm, 
multi-stage trial in infectious diseases, and showed that 
this design is feasible in a multicentre African setting, 
and can be used to assess many novel combinations. We 
identiﬁ ed a regimen that achieved our target and has 
promise to progress to phase 3, while discontinuing two 
regimens that did not show suﬃ  cient eﬃ  cacy, thereby 
saving on resources. 
This study has some limitations. It was not powered to 
be able to diﬀ erentiate between the experimental regimens, 
only between individual arms and the control regimen. 
The sample size to achieve such a power would be 
inappropriately large. Furthermore, it was not powered for 
assessment of relapse, which is the deﬁ nitive endpoint of a 
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pivotal trial but for time to culture conversion, which is an 
intermediate endpoint. Our newly developed phase 2c 
STEP trial design will address this issue in future trials,34 
and will improve conﬁ dence in a decision to move an arm 
into phase 3 based on a relapse endpoint.
Also, our objective was to identify regimens for 
future phase 3 assessment and thus our study does not 
provide information on the activity of individual 
experimental components. The study was only done in 
Africa and the HIV co-infected population was 
small. Therefore, future phase 3 trials should include 
sites from outside Africa and recruit representative 
proportions of HIV co-infected patients on anti-
retroviral treatment.
Another limitation is that because of the time 
required from sputum collection to determine negative 
cultures (which was necessary for our primary 
endpoint) and due to faster than expected recruitment, 
the interim analysis occurred late in the recruitment 
period. As a result, the multi-arm, multi-stage design 
resulted in a reduction in the ﬁ nal sample size of only 
2%. A real-time biomarker such as the molecular 
bacterial load assay could overcome this problem by 
replacing culture allowing the endpoint results to be 
available rapidly.35 Nevertheless, this was a crucial 
opportunity to assess the feasibility of this novel design 
in the context of an African multicentre infectious 
diseases clinical trial. In the future, larger trials with 
more arms, and higher patient numbers per arm will 
achieve more substantial cost savings through a multi-
arm, multi-stage design. These would also produce 
smaller conﬁ dence intervals, allowing a more precise 
estimate of the true HR. The collection of relapse data 
piloted in this study has been incorporated into our 
newly developed phase 2c STEP trial design.34 Such 
developments will provide the data to support the 
decision to move an arm into phase 3.
We have shown that 35 mg/kg rifampicin is safe and 
reduces time to culture conversion in liquid media. 
Importantly, the multi-arm, multi-stage concept has been 
shown to be feasible in a multicentre tuberculosis high 
burden setting, generating evidence to make a decision 
for whether or not to proceed to phase 3, and could 
greatly speed regimen development at reduced cost. In 
this phase 3 trial, a regimen with high dose rifampicin 
can be tested for safety and tolerability, potential to 
shorten duration of treatment, and ability to prevent the 
emergence of resistance to rifampicin. 
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